Pier Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Pier Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-17,262	Closed	-$4.09M	–	149
2014 Q3	$4.09M	Sell	17,262 -217	-1%	-$55.3K	0.65%	85
2014 Q2	$4.14M	Sell	17,479 -2,420	-12%	-$638K	0.59%	86
2014 Q1	$6.56M	Sell	19,899 -37,545	-65%	-$12.7M	0.85%	76
2013 Q4	$3.92M	Buy	+57,444	New	+$3.32M	0.52%	87

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pier Capital's ICPT Position: Q4 2014 in Review

Pier Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2014, closing a stake of 17,262 shares — an estimated $4.09M sold.

Pier Capital first reported a position in ICPT in Q4 2013 and held it in 4 quarters. The position peaked at $6.56M in Q1 2014. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2014.

Pier Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
Pier Capital sold 17,262 Intercept Pharmaceuticals, Inc. shares in Q4 2014, an estimated $4.09M.
Pier Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 4 quarters.
Pier Capital's Intercept Pharmaceuticals, Inc. position peaked at $6.56M in Q1 2014.
169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2014.

Based on Pier Capital's 13F filing for Q4 2014, filed 10 Feb 2015.